By Dr Eleni Lagkadinou (Vice President of Oncology Early Development at AbbVie)2024-12-13T10:04:54
Recent advancements in targeted therapies and immunotherapies are transforming lung cancer treatment. Discover how these innovations are improving outcomes and providing hope for patients.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-03-31T14:05:00Z
2026-03-30T09:54:00Z
2025-04-02T14:00:00
Sponsored by Eurofins Discovery
2025-10-08T14:00:00
Sponsored by Eurofins Discovery
2025-04-22T14:58:00
Sponsored by Takara Bio USA
2023-05-23T11:10:47
Sponsored by NanoTemper Technologies
2023-09-06T16:55:04
Sponsored by NanoTemper Technologies
2023-03-28T11:38:32
Sponsored by Bio-Techne
Site powered by Webvision Cloud